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Abstract 
Cystic fibrosis is the most common life-threatening autosomal recessive disorder in 
Caucasians. Recurrent pulmonary infection and inflammation are the major risk factors 
associated with cystic fibrosis. Microbial infection with highly resistant pathogens such as 
Burkholderia cenocepacia and Pseudomonas aeruginosa, is principally associated with cystic 
fibrosis. The effective management of pulmonary infection in cystic fibrosis patients is not 
controllable due to the multidrug-resistant strains and potential side effects of antibiotics usage. 
Liposomal encapsulation of macrolide antibiotics such as azithromycin show increased drug 
concentrations at the site of infection, along with reduced toxic effects. In this thesis work, 
liposome-loaded azithromycin formulation was prepared by dehydration-rehydration vesicle 
method and related characterizations including cytotoxicity were identified. The effects of 
liposomal azithromycin on biofilm community, purified bacterial virulence factors were 
determined and motility studies were performed in clinical isolate of P. aeruginosa. We found 
that liposomal azithromycin reduced biofilm activity, virulence factors production and bacterial 
motility. The liposomal formulation confirmed interactions between liposomes and bacterial 
membranes besides insignificant hemolysis or A549 cell toxicity. The end results collectively 
indicate that liposomal drug delivery systems could be a promising model to enhance the 
efficacy of antibiotics against resistant bacterial strains in lung infections. 
Keywords: Cystic fibrosis, Liposomes, Azithromycin. 
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2 
1 Introduction 
1.1 Cystic Fibrosis (CF) 
CF is a common lethal autosomal recessive disorder, which particularly affects 
Caucasians in the proportion of one in 2,500 persons.1,2 CF is a multi-organ disease primarily 
affecting lungs, pancreas, and sweat glands. Up to some extent, CF also affects organs such as 
the liver, gastrointestinal tract and reproductive organs.3,4 Out of every systems, the most 
affected is the pulmonary system. Consequently, pulmonary injury is the major clinical 
manifestation and the key reason for CF affected patient’s death.5 The underlying reason for CF 
pathophysiology is cause of CF is mutations in the Cystic Fibrosis Transmembrane Conductance 
(CFTR) gene.6,7 
1.1.1 Pathophysiology  
The defective CF gene causes malfunction in CFTR protein, and subsequent to this 
alteration, conductance of sodium and chloride on plasma membrane of the epithelial cell get 
deviated.8 The consequences are depletion of airway surface fluid and abnormal glandular 
secretions. The disease symptoms include, the mucus thickens and small airways are blocked 
(Diagram 1).9 The decreased intake of sodium and chloride ions, removal of bacteria by 
defective epithelial ciliary function bring about a stagnant sputum in the lungs, which also 
intensifies infection and inflammation.10 Followed by a condition known as bronchiectasis, the 
bronchi dilate and weaken, causing large airway obstruction.11 The continuous vicious cycle of 
airway obstruction is recurrent bacterial infection and inflammation that prompts a diminished 
lung function and  respiratory failure, a common cause of CF mortality.12  
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Diagram 1: Pathophysiology of Cystic Fibrosis Syndrome 
 
1.1.2 Cystic Fibrosis Transmembrane Conductance (CFTR) 
Approximately, 2000 CFTR mutations have been recognized and classified into 6 types 
based on their effects.13 The deletion of phenylalanine in the amino acid position at ∆508 is the 
most common mutation in CF community.14 The CFTR chloride channel is associated with the 
process of releasing Adenosine triphosphate (ATP) and coordinating other ion transport 
channels.15 CFTR is mainly circulated in respiratory epithelial cells, as well as the biliary tract, 
pancreas, and genitourinary system.16 
4 
1.1.2.1 Structure of CFTR protein 
The CFTR gene is based on the single arm of chromosome 7 and spans 250-kb of 
DNA.17,18 CFTR belongs to an Adenosine triphosphate (ATP)-binding cassette family of proteins 
and is a member of an ATP Binding Cassette (ABC) family.19 
The CFTR consists of 7 domains (Diagram 2): 
1) Intracellular amino and carboxyl terminal domains 
2) Two 6-segment Membrane-Spanning Domains (MSD) 
3) Regulatory (R) - domain 
4) Two Nucleotide-Binding Domains (NBD) 
The CFTR structure consists of sequential repeats of ABC pattern and is separated by a 
regulatory R-domain.20 The ABC pattern includes MSD, which is composed of six 
transmembrane stretches of amino acids followed by the NBD.21 The function of NBD is to bind 
and hydrolyze ATP to conduct chloride channel function. NBD-1 opens the chloride channel and 
NBD-2 closes the channel by ATP hydrolysis. This function is coordinated by phosphorylation 
of serine residues located in the R domain.22 
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Diagram 2: Structure of CFTR protein 
1.1.2.2 Types of CFTR mutations 
CFTR mutations are classified into six types based on mechanism of inducing disease 
and functions as shown in Diagram 3.23 The class I mutations, also known as stop mutations,  
regulates protein production and compromise approximately 10% of the total CF cases.16,24 Class 
II mutations consist of the most common ΔF508 mutations with typical CF symptoms.16 Class III 
(gating) mutations are rare and function in decreasing channel activation, which results in closure 
of the channels.25 Class IV mutations decrease ion conductance while,26 Class V mutations cause 
deformity in the CFTR molecules with reduced performance.27Lastly, Class VI mutations result 
in unstable proteins with an accelerated degradation. Collectively, these mutations affect the 
CFTR regulatory function on cell surfaces.16 
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Diagram 3: Types of CFTR Mutations 
 (Modified from Esther et al 2014) 
1.1.2.3 Function of CFTR in lungs 
In CF, lung disease is the main cause of morbidity and mortality, though it affects other 
organs as well. The gastrointestinal tract, liver, pancreas, and sweat glands equally contribute to 
the progression of the disease.28 The normal function of CFTR in the lungs is to regulate water 
and salt levels across the epithelial linings. In dysfunctional CFTR, hyper activity of epithelial 
sodium channels (ENaC) and failure of chloride ion to transport Cl- to the lumen result in the 
depletion of airway surface fluid (Diagram 4).29 Alterations in  ciliary beating and accumulation 
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of more mucus on the airway surface, makes the lumen a  favorable niche for microbial growth.30 
Gram-positive Staphylococci species, and Gram-negative Pseudomonas aeruginosa and 
Burkholderia cenocepacia species are the major opportunistic pathogens implicated in CF 
pulmonary infection.31,32 
 
Diagram 4: Function of Normal and Abnormal CFTR 
1.1.3 Comparison of normal and cystic fibrosis airways 
The normal airways are covered by two layers of mucus. The first is viscous fluid on the 
upper layer, and the second is periciliary fluid on the lower layer (Diagram 5).33 The mucus 
layers are needed for the continuous beating of epithelial cell cilia, which moves the mucus in a 
single direction flow towards the esophagus. During this process entrapped microorganisms in 
the mucus are carried away along with the flow. In the CF airways, the modifications in the 
mucus layers by abnormal ion secretion result in a uniformly sticky fluid that traps bacteria.34 
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Diagram 5: Comparison of Mucociliary Mechanism in Normal and CF Airways 
1.2 Microbiology of CF airways 
In a healthy individual’s lungs, the colonized bacteria are eradicated by the immune 
response of the body. However, the CF patient’s immune system overwhelmed by the bacterial 
colonization is unable to disperse the foreign bacteria residing in the lungs.35 In CF airways, 
infection is a conventional cohort of different microbial species such as S. aureus, H. influenzae, 
B. cepacia complex and P. aeruginosa.36,37 
S. aureus is non-motile, Gram-positive bacteria, facultative anaerobic microorganism 
mainly accountable for nosocomial and community-acquired infections.38 S. aureus are mainly 
responsible for causing pulmonary infections in CF patients.39 H. influenza is Gram-negative 
bacteria accountable for causing respiratory infections in both children and adults. 40 H. influenza 
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causes inflammation and damage to the airway.40 This damaged airway surface creates favorable 
conditions for colonization of P. aeruginosa in CF patients.41 S. aureus and H. influenza are the 
primary bacterial pathogens infecting the lungs of pediatric CF patients.42 
B. cenocepacia and P. aeruginosa are the major opportunistic Gram-negative pathogens 
associated with the infection, inflammation and mortality in adult CF patients.43,44 Gram negative 
P. aeruginosa and B. cenocepacia co-exist in the lungs of CF individuals and also form mixed 
biofilms during the infection process.35 In most CF cases, the P. aeruginosa colonization is 
followed by B. cenocepacia in the lungs and inhabits similar environmental conditions.45 It has 
been seen that the extracellular products of P. aeruginosa favor the settlement of B. cenocepacia 
by modifying the epithelial lining of the lungs in CF individuals.46 The interspecies cell-to-cell 
communication between P. aeruginosa and B. cenocepacia plays an important role in the 
production of virulence factors, biofilm development, and pathogenesis of CF.47 
The Burkholderia cepacia complex (BCC) are a group of related species (>20 species) 
mainly capable of causing respiratory infections.48 B. cenocepacia is the most prevalent bacterial 
pathogen, affecting 50% to 80% of CF population.49 This Gram-negative, rod-shape microbe 
mainly found in soil, plants, crops and any moist environment.50 B. cenocepacia has been 
reported in many CF cases for direct transmission between CF individuals and associated with 
increased mortality.51,52 B. cepacia complex species exhibited resistance to different 
antimicrobial agents as well.53 
P. aeruginosa is the most opportunistic human pathogen and a major contributor of 
pulmonary exacerbation in the CF population. It is a Gram-negative bacillus affecting the lower 
respiratory tract of the lungs, and is associated with higher morbidity and mortality compared to 
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other CF causing pathogens.54,55 P. aeruginosa is a ubiquitous micro-organism mainly found on 
plant surfaces, water, soil, and hospital enviornment.56 It is the most prevalent respiratory 
bacterial pathogen in CF individuals as well as individuals with compromised immune system.57 
It can acquired by 70% - 80 % of adolescence CF patients.58 P. aeruginosa colonization in the 
lungs is initiated by its adhesiveness with the help of epithelial cell receptors called 
asialogangloside-1 (GM1).59 P. aeruginosa is known as a ‘superbug’ because of its inherent 
resistance to antibiotics attributed to various resistance mechanisms including outer membrane 
impermeability, biofilm formation, drug inactivation and efflux pumps.60 
1.2.1 Biofilm formation 
A biofilm is a structured and organized syndicate of bacterial cells implanted in self-
produced polymer matrix attaching themselves to the living or abiotic surfaces (Diagram 6).61,62 
The matrix is made up of lipids, proteins, polysaccharides and extracellular DNA.63 Bacterial 
biofilms are resistant to disinfectants, antimicrobial drugs and components of the immune 
system.62 The bacteria in biofilm cause chronic bacterial infections leading to inflammation and  
continuous tissue damage.64 The formation of biofilm undergoes several steps to form a mature 
biofilm, which include primary attachment to the surface, microfilm formation, mushroom shape 
formation of biofilm, and a detachment stage to release motile bacteria.65 Type IV pili and 
flagella of P. aeruginosa are necessary for the formation of microcolonies and motility.66 
Quorum sensing signaling encoded genes rhl and rhlab are involved in the formation of 
mushroom-shaped biofilm structure.67 
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Diagram 6: Stages of Biofilm Formation 
The production of matured biofilm by P. aeruginosa takes approximately 5-7 days.62 The 
cycle of biofilm formation results in spreading planktonic bacteria to initiate new biofilm 
formation at different sites.68 The formation of biofilms can be prevented by early aggressive 
antibiotic therapy followed by ongoing suppressive antibiotic therapy.62,64 
1.2.2 Quorum Sensing  
P. aeruginosa utilizes a distinct mechanism called Quorum Sensing (QS) which is cell-
cell communication through signaling molecules produced in response to bacterial density.69 The 
intercellular communication among P. aeruginosa is induced by bacterial products which are 
able to diffuse from one cell to another cell.70 Quorum Sensing plays a significant role in  
regulating 10% of genes in the genome of P. aeruginosa.71 Quorum sensing mechanism of P. 
aeruginosa bacteria produces small molecules called autoinducers for the regulation of gene 
expression. P. aeruginosa the genes LasI and LasR are responsible for sensing cell density and 
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production of other regulated genes.30 The organism consists of two autoinducers (Diagram 7), 
N-butyryl-L-Homoserine lactone (C4-HSL) and N-3-oxo-dodecanoyl-L-Homoserine lactone 
(3O-C12-HSL) involved in exoproducts synthesis.72,73 QS signaling molecules regulate gene 
expression that controls production of different virulence factors and formation of biofilm, thus 
contributing to P. aeruginosa’s tolerance for antimicrobial chemotherapy.74,75 
 
Diagram 7: Quorum Sensing Signaling Molecules 
1.2.3 Virulence Factors 
P. aeruginosa releases different virulence factors such as rhamnolipids, pyocyanin, 
pyoverdine, lipase, chitinase, elastase and proteases, which can cause tissue damage, proteolysis 
imbalance and immunomodulation.76,77 Virulence factors released by P. aeruginosa provide 
favorable conditions for the settlement of bacteria and help in bypassing host immune 
responses.78 Rhamnolipids are microbial glycolipids and biosurfuctants favors P. aeruginosa in 
bacterial cell motility and formation of biofilm.79 Pyocyanin acts as both virulence factor and QS 
signaling molecule of P. aeruginosa, plays an important role in damaging pulmonary tissues.80 
Pyoverdine is an iron-chelating molecule (siderophore) of P. aeruginosa helps in the formation 
of flat biofilms and induces motility.81 P. aeruginosa produces hemolytic enzyme phospholipase 
C causes extensive tissue damage and inflammation during CF lung infections.82 After cellulose, 
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chitin is the most abundant polysaccharide found in nature and mainly on the bacterial cell walls. 
Chitinase possess mucolytic properties and are able to cause inflammatory (Type 2), allergic 
responses and remodeling of tissues.83 The elastase of P. aeruginosa is encoded by the LasB 
gene of Quorum sensing regulating genes, which mainly leads to the destruction of respiratory 
epithelium and degradation of different plasma proteins.84 Proteases (LasA elastase, LasB 
elastase and Alkaline proteases) are encoded by the LasA gene and play an important role in the 
disease progression of CF by damaging host tissue and remodeling tissues in the human 
airways.85 
1.2.4 Antimicrobial resistance of P. aeruginosa 
P. aeruginosa is a major opportunistic pathogen in the cause of CF population and its 
dissemination is very challenging to control because of its various multidrug-resistance 
mechanisms. The main mechanisms (Diagram 8) involved in the multidrug-resistance are 
bacterial biofilms, drug efflux systems, outer membrane permeability and enzymatic inactivation 
of the drugs.86 
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Diagram 8: Mechanisms of Multidrug-Resistance 
1.2.4.1 Bacterial biofilms 
Biofilms are embedded in the Extracellular Polymeric Substance (EPS) consists of 
polysaccharides and proteins that provide extra protection to the community.87 The EPS matrix 
prevents antimicrobial entry by anion exchange.88 The mutations in mucA gene with excess 
production of alginate provide further protection to bacterial biofilms.89 
1.2.4.2 Efflux pumps 
Efflux pumps are the major mechanism of the P. aeruginosa resistance to macrolide 
antibiotics. They prevent, through expulsion, drugs intake in to bacteria. The multidrug efflux 
15 
system of P. aeruginosa is comprised of three proteins, which are required for the effective 
removal of antibiotics from the bacteria.90 The three components of the multidrug efflux system 
include joining protein (MexA), outer membrane porin M (OprM) and energy-dependent situated 
in the cytoplasmic membrane of the bacteria (MexB).91 MexAB-OprM, MexCD-OprJ, and 
MexEF-OprN are the three components of the P. aeruginosa multidrug efflux system.92 The 
efflux pumps MexAB-OprM and MexXY-OprM contribute  to the intrinsic multidrug resistance, 
while hyper expression of MexAB-OprM, MexXY-OprM, and MexCD-OprJ provides acquired 
multidrug resistance.93 The major mechanism of macrolide resistance in P. aeruginosa biofilms 
is due to hyper expression of MexCD-OprJ efflux pump, which plays an important role in the 
antibiotic resistance.94 The MexCD-OprJ efflux pump is mainly expressed due to mutations in 
gene NfxB, which results in the increase of efflux genes and encodes a repressor of MexCD-
OprJ efflux pump expression.95 
1.2.4.3 Outer membrane permeability 
The reduced permeability or uptake is one of the resistance mechanisms involved in the 
multi-drug resistance to P. aeruginosa. The outer membrane permeability in Gram-negative 
bacteria such as P. aeruginosa is the major barrier for both hydrophilic and hydrophobic drugs.96 
The main characteristic feature of Gram-negative bacteria like P. aeruginosa are an outer 
lipopolysaccharides (LPS) layer and inner phospholipids layer.97 Cell membrane of P. 
aeruginosa contains porin proteins like OprD, which acts as passage way for various 
antimicrobial drugs or small chemical entities.98 The reduced outer membrane (OM) 
permeability and presence of multi-drug efflux systems in P. aeruginosa work together, result in 
reduced antimicrobial drugs uptake.99 
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1.2.4.4 Enzymatic inactivation  
The bacterium also exhibits multidrug-resistance as it comprises unique characteristics of 
inactivating enzymes and decreases the antibiotic activity of macrolides.100 The group 
transferases is the class of resistant enzymes that inactivates the macrolide antibiotics by 
chemical substitution.86 The modifications in antibiotics done by group transferases alter 
structural modifications (features) and impair the target site binding. The chemical strategies 
required for this process are O-acylation, N-acylation, O-phosphorylation, O-ribolysation, O-
nucleotidylation and transfer of thiols.86 Hydrolysis also causes antibiotic inactivation by 
targeting and cleaving the amides and esters chemical bonds prior to reaching target in bacteria. 
The target-site modification by methylation or mutation also prevents the binding of the 
antibiotic to its ribosomal target.95 
1.3 Management of CF 
1.3.1 Chest physical therapy 
Chest Physical Therapy (CPT), also known as postural drainage and percussion, is the 
most widely used treatment in CF individuals. It is used for by clearing mucus from the airways 
of the CF lungs.101 Excess mucus is removed from the CF lungs by using mechanical devices or 
different physiotherapy techniques.102 The major drawbacks of CPT are that it is time-
consuming, uncomfortable, and unpleasant to CF patients.  
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1.3.2 Lung transplantation 
Lung transplantation is a major life-saving form of therapy for respiratory failure in CF 
patients associated with high-risks.103 Lung transplantation in CF patients can increase 
significant survival rates and improve quality of life.104 
1.3.3 Mucus thinning drugs 
Mucus thinning drugs, also known as mucolytics, are designed to modify the biophysical 
properties of the mucus and reduces mucus elasticity and viscosity.105 Depending upon the mode 
of action, mucolytics are classified as classic mucolytics, peptide mucolytics and non-destructive 
mucolytics.106 The most widely used mucolytics are N-acetly L-cystiene (NAC), which acts by 
disrupting disulfide bonds of mucoproteins and dornase alfa by breaking down DNA 
enzymatically in the mucus.107,108 
1.3.4 Bronchodilator therapy 
Bronchodilator therapy is one of the most frequently used treatments for CF patients. 
Bronchodilators act by relaxing the smooth muscles of the airways and preventing bronchospasm 
in CF patients.109 Bronchodilators are available in short-acting and long-acting medications and 
can be administered by dry powder inhaler, nebulizer and aerosol forms.110 The short-acting drug 
salbutamol was widely used prior to CPT, which helps to open airway passages and drain mucus 
from the lungs of CF patients.111 The long-acting drugs such as salmeterol and formoterol are 
used for the treatment of bronchoconstriction and have shown improved lung function in CF 
patients.112 
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1.3.5 Anti-inflammatory therapy 
Various kinds of anti-inflammatory drugs are used in the treatment of CF to reduce the 
effects of inflammation in airway passages and lungs.113 Higher levels of inflammatory 
responses like cytokines, neutrophils and chemokines are primarily associated with lung 
infection in CF.114 The increased rate of inflammation results in destruction of the lung 
parenchyma and alterations in the mucociliary movements.115 The oral corticosteroids such as 
prednisone are rarely prescribed for the treatment of CF for short term because of their potential 
side effects.116 Inhaled corticosteroids such as beclomethasone and fluticasone deliver the drug 
directly to the lungs, thus causing less side effects in comparison to oral corticosteroids.117 Non-
steroid anti-inflammatory (NSAIDs) drugs such as ibuprofen are widely used in the treatment of 
CF as they possess major potential clinical benefits despite side effects like gastrointestinal 
hemorrhage.118 The macrolide antibiotic azithromycin possesses both anti-inflammatory and 
immunomodulatory effects and has also shows an improved outcome in CF patients for extended 
usage.119  
1.3.6 Antibiotic therapy 
A wide range of antibiotics such as aminoglycosides, β-lactams, fluoroquinolones and 
macrolides are extensively used to control inflammation and Pseudomonas infections.120,121 The 
goal of antibiotic therapy is to improve the quality of life for CF patients, and to decrease 
symptoms through reducing susceptibility to microbial infections.122,123 The combination therapy 
of at least two antibiotics is more effective against various resistant strains and delayed resistance 
development compared to monotherapy. Aminoglycosides are common to use for respiratory 
infections however, side effects are associated thus constraint their clinical application and uses. 
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124 β-lactams are broad range of spectrum of antibiotics consisting of β-lactam ring in their 
structure and their usage related with allergic reactions in CF patients. Fluoroquinolones are 
broad spectrum antibiotics used in the treatment of respiratory and urinary tract infections, 
however side effects like hepatotoxicity is associated with their usage.  Alternatively, for 
pseudomonas lung infections, macrolide antibiotics can be used as its possess dual properties 
(Anti-microbial and Anti-inflammatory) and a few side effects.125 
1.3.6.1 Macrolides 
Macrolides are a group of chemical compounds, which have a large lactone ring in their 
structure (Diagram 9).  
 
Diagram 9: Lactone Ring Structure 
They are mainly classified based on the number of lactone rings: 14-membered 
compounds (erythromycin and clarithromycin) and 15–membered compounds (azithromycin) 
(Diagram 10).126 The 14-membered compound (erythromycin and clarithromycin) consists of 
lactone ring, oxygen, carbon and monobasic charge.127 The 15–membered compound 
(azithromycin) has an azalide ring, oxygen, carbon, nitrogen and dibasic charge. The differences 
in their structures of macrolides impact their effects on antimicrobial activity and 
pharmacokinetic profiles.128 The macrolide antibiotics are widely used in the treatment of 
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intracellular pathogens, Gram-negative bacteria, and for several Gram-positive bacteria.129,130 
Macrolides play a key role in the treatment of intracellular bacterial infections by marked cell 
penetration and increased tissue accumulation.131 They also possess anti-inflammatory properties 
in both in vitro and in vivo, thus allowing more clinical benefits.132 
 
Diagram 10: Chemical Structures of Macrolides 
The macrolide antibiotics act as an antimicrobial by reversibly binding to the 50s subunit 
of the bacterial ribosome, which inhibits the RNA-dependent protein synthesis by preventing the 
reactions of trans-peptidation and translocation (Diagram 11).133 The 14 and 15-membered ring 
chemical structures of macrolides are more likely potent inhibitors of natural mRNA-directed 
peptide synthesis.134 
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Diagram 11: Mechanism of Action of Macrolides 
Erythromycin belongs to the first class of macrolide antibiotics containing 14-membered 
lactone ring, which adhere to two sugar moieties.135 Erythromycin is primarily used in the 
treatment of upper respiratory tract and skin infections.136 It is also used effectively for the 
treatment of infections caused by intracellular pathogens like Legionella, Mycoplasma and 
Chlamydia.137 The anti-inflammatory effect of erythromycin also plays an important role in the 
treatment of lower respiratory tract infections and inflammation, in combination with other 
drugs.138 
Clarithromycin is derived from erythromycin by substituting a methoxy group for the C6-
hydroxyl group.127 This substitution in the chemical structure causes the clarithromycin to be 
more stable in acid, reduces gastrointestinal intolerance and improves bioavailability properties. 
139 At sub-inhibitory doses, clarithromycin was effective in the treatment of P. aeruginosa 
biofilms. Compare to erythromycin, it showed similar properties against Gram-negative 
organisms in vitro.140 Erythromycin and clarithromycin also demonstrated enhanced activity 
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against H influenzae and S pneumonia.141Moreover, Clarithromycin was used effectively in the 
treatment of H pylori- associated peptic ulcer disease.142 
Azithromycin has antimicrobial and anti-inflammatory characteristics that makes more 
effective than erythromycin and clarithromycin.143 Following the azithromycin pharmacokinetic 
profile only a single dose regimen per day is require for a short period of time which varies from 
3 to 5 days whereas erythromycin and clarithromycin needed two- times dosage regimen for a 
period of 7 to 14 days.144 Azithromycin is an second generation, broad-spectrum antibiotic used 
in the treatment of lower respiratory tract infections.145 It is developed by inserting methyl-
substituted nitrogen in the position of carbonyl group at the 9a position of the aglycone ring.127 
The resulting structure formed after this modification is referred to as an “azalide”.145 This 
structural modification makes the compound more stable in acid, and increases tissue penetration 
and serum half-life.144 This modification also decrease activity against some Gram-positive 
organisms and increases activity against Gram-negative organisms.146 The use of azithromycin 
proved effective anti-mycobacterial effect in the treatment of Mycobacterium avium disease in 
HIV infected patients.147 Azithromycin can be used as a cell–to-cell blocking agents affecting the 
formation of biofilm in P. aeruginosa.148 It has been demonstrated that azithromycin at sub-
inhibitory concentrations can inhibit P. aeruginosa virulence factor levels.149 Study has shown 
that azithromycin attenuated alginate production at sub-inhibitory levels in P. aeruginosa.150 In 
CF infected mice azithomycin exhibited anti-inflammatory effects by reducing cytokine release 
and cellular infiltration.151 The study has proven for CF patients that prolonged usage of 
azithromycin shows more improved clinical outcomes.152 Azithromycin has the properties of 
high level accumulation and retention in cells and tissues in comparison to erythromycin.153,154 
Azithromycin accumulates effectively in the phagocytes of cells and increases supply of drug to 
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the infected sites.155 The azithromycin dosage of 500 mg/ daily for a 3-day course used for lower 
respiratory tract infections  therapy.156 A study showed that the typical use of azithromycin is not 
effective against P. aeruginosa infections because of the bacterial outer-membrane 
impermeability and efflux pump.157 The usage of azithromycin in higher doses resulted in 
increased serum levels and hepatotoxicity due to the catalytic ability of cytochrome CYP3A4.119, 
158  
Macrolides exhibit anti-microbial resistance by presence of efflux pumps and target site 
modification by methylases (Diagram 12). The multidrug efflux pumps of P. aeruginosa actively 
transport antibiotics macrolides out of the cell. MexB efflux pump of P. aeruginosa plays a 
prominent role in anti-microbial resistance of macrolides. The target-site modification by 
methylation or mutation also prevents the binding of the macrolide antibiotic to its ribosomal 
target. 
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Diagram 12: Resistance Mechanisms of Macrolides 
In order to overcome the problem of multi drug resistant P. aeruginosa and macrolide 
toxicities, safe drug delivery systems such as micelles, dendrimers, nanomers, and liposomes are 
essential.159 Micelles are self-assembled nanostructures formed in the aqueous solution 
comprising of amphiphilic copolymer blocks.160 The major advantages of micelles drug delivery 
are longer circulation and improved solubility of hydrophobic drugs, although its instability is a 
drawback. 161Dendrimers are three dimensional, uniformly distributed macromolecules with 
hyper branched.162 Dendrimers are an exemplary drug delivery system due to high water 
solubility, precise molecular weight, polyvalency and biocompatibility.163 Solid nano particles 
are new generation submicron-sized lipid emulsions used alternative to other microparticles.164 
The advantages of solid nanoparticles are increased drug stability, feasibility in loading drugs 
and easier large scale production, while drawbacks include low drug loading.165 Among all of the 
different types of drug delivery systems, liposomes have more leverage because of their 
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remarkable characteristics such as upsurge therapeutic index of encapsulated drugs and reduces 
drug toxicity.166 
1.4 Liposomes 
 Liposomes are small and round lipid vesicles with sizes ranging from nanometers to 
micrometers (Diagram 13).167 Liposome consists of one or more surrounding lipid bilayers and 
an aqueous core, as well as a hydrophilic head group and hydrophobic tails.168 Liposomes are 
considered among the safest and most reliable drug delivery systems since they are 
biodegradable and biocompatible.169 
 
Diagram 13: General Structure of Liposome 
Liposomes are broadly classified into three types depending on their size and bilayers: as 
shown in Diagram 14. 
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Diagram 14: Classification of Liposome by Size 
(a) Multi Lamellar Vesicles (MLVs) 
− Usually size ranges about > 0.1 µm  
− It consists of more than one bilayer 
− Prepared by thin-film hydration method or hydration of lipids 
(b) Large Unilamellar Vesicles (LUVs) 
− Usually size ranges about > 0.1 µm  
− It consists of single bilayer 
− Prepared by detergent dialysis method, ether injection method and reverse phase 
evaporation technique (REV) method 
(c) Small Unilamellar Vesicles (SUVs) 
− Usually size ranges about ≤ 0.1 µm  
− It consists of single bilayer 
− Prepared by using sonicator or extruder 
MLVs LUVs SUVs
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1.5 Liposomal drug delivery systems 
1.5.1 Phospholipids 
Liposomes are composed of natural or synthetic phospholipids. Different kinds of 
phospholipids are employed in the preparation of lipid vesicles. The most commonly used are 
phosphatidylcholines (PC), phosphatidylethanolamines (PE) and phosphatidylserines (PS) 
(Diagram 15).170,171 In order to increase the stability and permeability, cholesterol has been used 
in the bilayer formation of the liposome. Phospholipids have different net charges based on the 
content of the liposomes such as dipalmitoylphosphatidylcholine (DPPC) which has a neutral 
charge, dimethyldioctadecyl-ammonium bromide (DDAB) has cationic charges, and dicetyl 
phosphate (DCP) has anionic charges.172 
 
Diagram 15: Structures of Phospholipids 
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1.5.2 Phase transition temperature 
Phase transition temperature is required to change the phospholipid’s physical states from 
ordered gel to disordered gel phase, which occurs due to the conversion of hydrocarbons.173 
Hydrocarbons are tightly packed and fully extended to the disordered stage and make more fluid. 
The lengths of the hydrocarbons, the charge on the lipids and head group species are the major 
factors that affect the phase transition temperature of the phospholipids. Increase in the 
temperature (Tm) of the phospholipid bilayers results in disordered chains making lipids more 
fluid. The phase transition temperature of the phospholipids can be measured by Differential 
Scanning Calorimetry (DSC) analysis.174 Some of the important phase transition temperatures of 
phospholipids are DPPC (Tm =41° C), DSPC (Tm =55° C) and DMPC (Tm =23°C).175 
1.5.3 Methods of preparation 
 Numerous methods have been employed to prepare the liposomes (Diagram 16). The 
method developed by Bangham is the first and most widely used method in the preparation of 
multilamellar liposome vesicles (MLVs).176 
 
Diagram 16: Methods of Liposome Preparation 
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1.5.3.1 Conventional methods 
Conventional method mainly involves the dissolution of lipids in an organic phase 
followed by the addition of aqueous solution.177 
(a) Dehydration Rehydration Vesicles (DRV) method 
DRV is the simplest and most widely used method for preparing the liposomes.178 The 
initial step in the preparation of DRVs involves dissolving of lipids in organic solvents such as 
chloroform or a mixture of chloroform/methanol in a round bottom flask. This step is followed 
by evaporating the organic phase to form a thin layer of lipid film.179 The following step involves 
rehydration of the lipid film with an aqueous phase. On rehydration of dried lipid films the 
lamellae are formed, the last step involves applying mechanical agitation such as shaking or 
vortexing to detach the lipid film from the flask. The key advantage of this method is simple, 
higher encapsulation efficiency and more stability. Different varieties of lipids and drugs can be 
encapsulated using this method. I used DRV method for the preparation of liposomes in this 
study as it provides higher encapsulation efficiency of loading macrolide drug azithromycin. The 
major drawbacks of this method are lower entrapment of drugs and retention. 
(b) Reverse Phase Evaporation (REV) method 
The preparation of liposomes by REV method involves high aqueous space, which 
enables to entrap a high amount of the aqueous material.166 The liposomes prepared through the 
REV method can be made from different varieties of lipids or lipid mixtures. The liposome 
preparation by this method involves two phases; First water-in-oil emulsion is formed by the 
limited sonication of a two- phase system containing phospholipids in different organic solvents 
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such as diethyl ether or isopropyl ether. Later, the organic solvents are removed by reduced 
pressure generating viscous gel. Under reduced pressure conditions and with continuous rotary 
evaporation the excess formed solvent is removed resulting in the formation of liposomes.180 The 
major advantages of this method are effective loading of macromolecules, while the drawbacks 
are a need for organic chemicals, and mixtures of LUVs and MLVs are formed. 
(c) Injection method 
The preparation of liposomes by injection method is done though ethanol/ether.181 The 
lipids are dissolved in the ethanol or ether and the lipid solution is slowly injected in to the 
aqueous phase. The next step involves the evaporation of organic solvent, resulting in the 
formation of unilamellar liposomes. The major advantages of this method include sterility, can 
be done heating and narrow vesicles of liposome can be obtained.182 
(d) Detergent removal method 
In this method of liposome preparation, different kinds of detergents are used in lipid 
solubility.183 The detergent is removed by methods such as dialysis, column chromatography and 
adsorption, resulting in the formation of micelles, which then leads to formation of liposomes. 
The significant advantage of this method is its extreme flexibility, which allows for the 
preparation of various varieties of liposomes. 
1.5.3.2 Mechanical methods 
In these methods, mechanical force is applied in order to alter the liposome size and 
lamellarity.184  
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(a) Sonication 
It is the first most widely used and least complicated method in the liposome size 
reduction process by mechanical treatment. The two major techniques used in the preparation 
are: i) probe sonication; and ii) bath sonication. Probe sonicator is a better method to prepare 
SUVs on a small scale, because the process involves high energy input into lipid dispersions, 
which can be applied directly on the MLVs.166 Bath sonicator is a commonly method used in the 
preparation of liposomes for large quantity scale. It is the most widely used method for the 
small-scale preparation of SUVs with the highest input of energy into lipids. 
(b) Extrusion 
The extrusion method of preparing liposomes involves liposome size reduction by 
passing them through the polycarbonate filters of different pore sizes with repeated cycles of 
extrusion under moderate pressure.185 Extrusion is a simple technique without use of any volatile 
organic compounds, but requires high-pressure nitrogen gas in the extruder. Drawbacks include a 
more time consuming process of size reduction. 
(c) Microfluidization method 
Microfluidizer/Microemulsification is a technique widely used in the large scale 
production of liposomes in the pharmaceutical industry.186 The microfluidizer pumps fluid at 
high pressure along channels of small size, which later divides the fluid into two streams, 
resulting in collision at high velocity. Factors like turbulence and cavitation result in the 
production of small size liposomes and polydispersity. The disadvantage of this method is 
requirement of high pressure for size reduction causing lipid degradation. 
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1.5.4 Methods of characterization 
(a) Particle size 
The particle size and distribution (polydispersity index) of the liposomes are important 
parameters for characterizations. Particle size affects the therapeutic use and mode of 
administration. The size of the liposome is also related to the RES uptake. Dynamic Light 
Scattering (DLS) is one of the suitable methods to measure the particle size.187 The principle 
involved in DLS method is diffusion co-efficient based on Brownian motion.188 Key drawbacks 
of this DLS technique are that it can measure only the particle size but does not give any 
information regarding the morphology of particles, as well as its limitations in measuring the 
polydispersity samples. The electron microscopy is an alternative method used to characterize 
the particle size. It is an enhanced technique, however, and some limitations with the sample 
size. It have is not suitable for monitoring the stability of the sample. The size of liposomes can 
be reduced through methods like sonication, extrusion, and micro fluidization techniques.189 
(b) Lamellarity 
Lamellarity is a parameter used to measure the average particle size in relation to the 
amount of drug entrapped inside the liposome.190 Lamellarity is mainly done by phosphorus 
nuclear magnetic resonance (P-NMR) technique, which is mainly based on the signals response 
to the addition of magnesium ions (Mn2+). Other methods such as NMR, Small Angle X-ray 
Scattering (SAXS) and Electron microscopy are used to characterize the zeta potential of 
liposomes.191 
(c) Zeta potential 
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The zeta potential is an important parameter used in the characterization of liposomes to 
measure the overall charge of the liposomes.166 Zeta potential has an effect on pharmacokinetic 
properties of liposomes in the body and also impact the phagocytosis of the liposomes in the 
blood stream.192 It is also used to measure the stability of the liposomes and helps in 
understanding the controlling factors like fusion and precipitation of liposomes.166 
(d) Encapsulation efficiency 
Encapsulation efficiency is an important method used to measure the quantity of drug 
entrapped inside the liposomes that is commonly used to optimize the formulation.193 
Encapsulation efficiency is generally defined as a percentage of entrapped drug to the initial 
concentration of drug in the solution. The lipophilic drugs are usually entrapped in the lipid 
bilayers and hydrophilic drugs are incorporated in the aqueous core. Triton X 100 is a detergent 
used to rupture the vesicles during the measurement of encapsulation efficiency.193 Alternate 
methods like High Performance Liquid Chromatography (HPLC), spectrophotometry and 
microbiological assays are also used to determine the encapsulation efficiency. 
1.5.5 Applications of liposomes 
Liposomes are used as a drug delivery system due to unique and special characteristics. 
194,195 The liposomal drug delivery system differs from other drug carriers as it releases the drug 
either in the blood plasma or at the site of application.196 The liposomal drug delivery systems 
for pulmonary delivery have been widely used in the treatment of CF by encapsulating different 
kinds of drugs such as antimicrobials, anti-oxidants, and cytotoxic.197 
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1.5.5.1 Liposomal formulations in the market or in clinical trial pipeline 
In recent years, there has been a tremendous development in liposomal technology. Many 
of these liposomal formulations are under clinical trials, and a few have already approved for 
human use by the US FDA (Table 1).198, 199 Purpose of using liposomal drug delivery systems is 
to reach the target selection of active drug in different sites of the carcinoma and inflammated 
areas.200,158 In cancer treatment, liposomal products such as Doxil® and DaunoXome® have 
been approved successfully at first for the treatment of Kaposi Sarcoma.201,202 For serious fungal 
infections, the liposomal formulations such as Ambisome®, Amphacil® and Abelcet® have also 
been approved.203 AmBisome® was approved for the treatment of aspergillosis, cryptococcosis 
and candidiasis.204 Recently, the FDA approved vincristine liposomal formulation Marqibo® for 
the treatment of acute lymphoblastic leukemia.205 
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Table 1: Approved liposomal products for human usage  
Product Drug Lipid Composition Route of 
Administration 
Manufacturer Approved treatment References 
AmBisome Amphotericin B HSPC,DSPG & CHOL Intravenous Gilead Sciences (USA) Fungal infections 206, 204 
Doxil Doxorubicin HSPC, CHOL & 
DSPE-PEG2000 
Intravenous Johnson & Johnson 
(USA) 
Kaposi’s Sarcoma, Breast and 
Ovarian cancer 
207, 208 
Lipo-Dox Doxorubicin HSPC, CHOL & 
DSPE-PEG2000 
Intravenous Sun Pharma (India) Kaposi’s Sarcoma, Breast and 
Ovarian cancer 
209, 210 
Myocet Doxorubicin EPC & CHOL Intravenous Sopherion Therapeutics 
(USA) 
Breast cancer 211, 212 
DepoCyt Cytarabine DOPC, DPPG, CHOL 
& Triolein 
Spinal Pacira Pharma (USA) Lymphomatous meningitis and 
neoplastic 
213, 214 
DepoDur Morphine DOPC, DPPG, CHOL 
& Triolein 
Epidural APP Pharma (USA) Pain treatment 215, 216 
DaunoXome Daunorubicin DSPC & CHOL Intravenous Galen (USA) Kaposi’s Sarcoma, Blood cancer 217, 218 
Marqibo Vincristine Egg sphingomyelin & 
CHOL 
Intravenous Talon Therapeutics 
(USA)  
Acute lymphoblastic leukaemia 219, 220 
Visudyne Verteporphin EPG & DMPC Intravenous Bausch & Lomb (USA) Photodynamic therapy 221, 222 
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In the pipeline, two liposomal formulations for the treatment of P. aeruginosa infections 
are shown in (Table 2), Liposomal amikacin formulation (Arikace) in phase III clinical trial is 
used by inhalation for the treatment of CF, Non CF and bronchiectasis.223  Another formulation 
in phase III clinical trial, Liposomal ciprofloxacin (Lipoquin) manufactured by Aradigm and 
administered through inhalation is intended for the treatment of CF, Non CF, and 
bronchiectasis.224,225 The clinical results of these formulations for treating P. aeruginosa 
infections in CF patients provided positive results for further investigations. 
Table 2: List of liposomal products in clinical trials stage for the treatment of P. 
aeruginosa infections  
Product Drug 
Lipid 
mixture 
Route of 
Administration 
Manufacturer 
Target 
treatment  
Stage References 
Arikace Amikacin 
DPPC & 
CHOL 
Inhalation Insmed (USA) 
Lung 
infections  
Phase 
III 
226, 227 
Lipoquin 
Cipro 
floxacin 
HSPC & 
CHOL 
Inhalation 
Aradigm 
(USA) 
Lung 
infections 
Phase 
III 
228, 229 
Pulmaquin 
Cipro 
floxacin 
HSPC & 
CHOL 
Inhalation 
Aradigm 
(USA) 
Lung 
infections 
Phase 
III 
230, 231 
1.5.5.2 Applications of Liposomal Antibiotics—Evidences from In vitro and In vivo 
studies: 
The key focus of developing new liposomal antibiotic formulations is to increase the 
therapeutic efficacy of drugs at the site of infection and reduce toxicity.231 Liposomes are the 
most widely used nanodevices for the encapsulation of some antibiotics for the treatment of 
several intracellular and extracellular infections (Table 3).232 Research suggest that liposomal 
encapsulated antibiotics have less toxic effect than the conventional administration of 
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antibiotics.233 Less frequency of dosing and increased fusion of antibiotic with infected cells are 
major significant characteristics of the liposome-encapsulated antibiotics.234 
Table 3: Liposomal antibiotics used for various bacterial infections 
Liposomal entrapped 
antibiotics  
Bacteria References  
In vitro In vivo 
Azithromycin P. aeruginosa, MAC  158, 235 
Clarithromycin P. aeruginosa, MAC MAC 236, 237, 238, 
239 
Erythromycin P. aeruginosa  193, 240 
Amikacin P. aeruginosa, B. cenocepacia, 
MAC, M. tuberculosis, S. 
aureus  
MAC, M. tuberculosis 241, 242, 243, 
244,245, 238 
Gentamicin P. aeruginosa, B. cenocepacia, 
MAC, E. coli, K. pneumoniae  
K. pneumoniae, S. enterica, B. 
abortus 
246, 247, 248 
249, 250 
Tobramycin P. aeruginosa,  B. cenocepacia,  
B. cepacia, S. aureus E. coli, S. 
maltophilia  
P. aeruginosa,  B. cepacia 251, 252, 241 
242, 253, 254 
Vancomycin  S. aureus, S. epidermidis, 
MRSA  
MRSA 255, 256, 257 
Polymyxin B P. aeruginosa,  E. coli, K. 
pneumoniae, B. bronchiseptica 
P. aeruginosa 258, 259, 260 
261 
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Enormous research has been done for the application of liposomes as drug delivery systems 
by In vitro and In vivo studies in the treatment of several infections. The liposomes show 
increased drug concentrations at the site of infection along with reduced toxic effects.262 One 
study has shown that erythromycin was able to be encapsulated in liposomes with higher efficacy 
and more stability.193 The encapsulation of liposomes with antibiotics like aminoglycosides and 
macrolides can enhance their effect in the treatment of P. aeruginosa infections.248 Compared to 
free tobramycin, liposome- loaded tobramycin shown effective in eradicating Gram-negative 
bacteria.263 Furthermore, clarithromycin loaded liposome demonstrated increased antibacterial 
effects against P. aeruginosa and decreased toxic effects on the human lung cells.236 For M. 
avium infections, liposome encapsulated azithromycin or ciprofloxacin focus on the 
reticuloendothelial system, which provided efficient direct delivery of antibiotics into the 
infected cells resulting in a more effective treatment.235 The liposomes loaded with 
aminoglycoside antibiotics showed admirable results in the treatment of bacterial infections. 
Liposomal Amikacin for Inhalation (LAI) is a new formulation under clinical trial showing 
promising results to maintaining lung function and reduced pulmonary exacerbations.264 The 
encapsulation of amikacin in liposomes resulted in a higher concentration of the drug in infected 
tissues in murine model of M. avium infected mice.265 
The major drawbacks of liposomal antibiotics are lower encapsulation efficiency, shorter 
shelf-life and sterility problems.231 The encapsulation efficiency is a considerable factor in the 
therapeutic efficacy of liposomes.266 The preparation of liposomes by DRV method 
demonstrated higher encapsulation efficiency with a better stability of macrolides and 
aminoglycosides.193 Shorter shelf-life of liposomes can be influenced either by physical or 
chemical processes. Few studies reported that upon intravenous administration of liposomes it 
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could lead to lower stability and short circulation in the blood stream.267 The sterilization process 
of the phospholipids used in the preparation of liposomes is a time consuming and expensive 
method of liposome preparation at a larger scale. These are some of the major disadvantages of 
liposomal drug delivery systems, and they have not yet been addressed scientifically.166,262 
For future prospects, developing new liposomal antibiotic formulations is essential for the 
treatment of CF caused by P. aeruginosa infections. The unique characteristics of liposome as a 
drug delivery system advance the development of new liposomal formulations with more 
biocompatible and therapeutic efficacy of drugs.  
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1.6 Thesis objective 
The objectives of this research study are:  
− To characterize liposome encapsulated azithromycin formulation and evaluate its 
antimicrobial effects against P. aeruginosa. 
− Examine the liposomal azithromycin effects on biofilm activity and virulence 
factors, quorum sensing reduction, motility at sub-inhibitory levels. 
− To investigate the mechanism of bacteria and liposome interactions. 
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Abstract 
Objectives: This work has been carried out to construct a novel liposomal azithromycin 
formulation and examine its antimicrobial effects against P. aeruginosa.  
Methods: The liposomal azithromycin formulation was prepared by the dehydration-
rehydration vesicle method and its characterisations were tested. The minimum inhibitory 
concentration (MIC) and minimum bactericidal concentration (MBC) of liposomal formulation 
was determined by microbroth dilution method. Liposomal azithromycin activity against biofilm 
forming P. aeruginosa was assessed using Calgary biofilm device. The effect of subinhibitory 
concentrations of liposomal azithromycin on bacterial virulence factors and motility studies was 
performed on P. aeruginosa strains. The bacteria and liposome interactions were studied by 
using flow cytometry analysis. The toxicities of the liposomal formulation on erythrocytes and 
A549 lung cells were evaluated in vitro. 
Results: The average diameter of the liposomal azithromycin was found to be 406.07+ 45 
nm and encapsulation efficiency was 23.8 ± 0.2 %. The MIC and MBC values of liposomal 
azithromycin were significantly lower than the free azithromycin. The liposomal azithromycin 
significantly reduced the bacteria in the biofilm and attenuated different virulence factors 
production; it also reduced the different patterns of bacterial motilities. By flow cytometry 
analysis data, it was shown that there are interactions of liposomes with the bacterial membranes. 
No significant hemolysis or cell toxicity was observed with liposomal formulation.  
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Conclusions: The results of this research indicate that this novel liposomal azithromycin 
formulation could be a useful therapy to enhance the safety and efficacy of azithromycin against 
P. aeruginosa infected persons. 
Keywords: Cystic fibrosis, Liposomes, Azithromycin 
2.1 Introduction 
Cystic fibrosis (CF) is a life-threatening autosomal recessive hereditary disorder, which 
usually affects Caucasian populations in the ratio of one among 2,000 newborns.268-270 It is also 
considered as a multi-functional or multi-systemic disease, as it affects several organs and 
systems of the body like liver, pancreas, gastrointestinal tract, reproductive system and lungs in 
particular.3,271 Among all these organs, pulmonary injury is mainly responsible for patient death 
in the cystic fibrosis population.4 Recurrent pulmonary infection and inflammation are the major 
risk factors associated with cystic fibrosis disease.272 Cystic fibrosis is caused by the mutations in 
the cystic fibrosis transmembrane conductance (CFTR) gene.273 Approximately 2000 CFTR 
mutations have been identified that can be classified into 6 types based on their effect.13 The 
deletion of phenylalanine in the amino acid position at ∆508 is the most common mutation, 
which is responsible for the majority of cystic fibrosis cases.14 The normal function of CFTR in 
lungs is to regulate the water and salts across the epithelial cells, whereas in the abnormal or 
dysfunctional CFTR in the lungs there is hyper absorption of sodium from the epithelial surface, 
which results in the depletion of airway surface liquid on the surface.274  All these changes in 
airway surface depletion lead to the prevention of normal ciliary beating and accumulation of 
more thick and sticky mucus on the airway surface, which leads to favorable conditions of 
microbial colonization. 37 The major opportunistic pathogens implicated in pulmonary infection 
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are Gram-positive Staphylococci species and Gram-negative Pseudomonas aeruginosa and 
Burkholderia cenocepacia.31 The Toxic Shock Syndrome Toxin-1 (TSST-1), coagulases and 
proteases are the virulent factors produced by the Staphylococci species.275 The P. aeruginosa 
releases large number of virulence factors like lipase, chitinase, elastase, protease, exotoxin A, 
neuraminidase, catalase and superoxide dismutase.276,277 Siderophores, lipases and proteases are 
the virulence factors released by the B. cepacia.278 
Among all bacteria, the most opportunistic human pathogen is P. aeruginosa mainly 
responsible for pulmonary exacerbation in CF population.279,280 It is a Gram negative bacillus, 
which mainly affects the lower respiratory tract of the lungs; a ubiquitous organism mainly found 
on the surface of plants, water, soil and hospital areas.281 It is the most prevalent respiratory 
bacterial pathogen that affects cystic fibrosis individuals with compromised immune systems.282 
Nowadays it is called ‘superbug’ because of the P. aeruginosa engendered resistance.283  P. 
aeruginosa exhibits different kinds of resistance mechanisms by outer membrane 
impermeability, and through efflux of the antibiotic.134,284 P. aeruginosa comprises a mechanism 
called quorum sensing (QS) which is cell-cell communication of signaling molecules produced 
in response to bacterial density.69 Quorum sensing signaling molecules regulates gene expression 
that controls the formation of biofilm and production of different virulence factors thereby 
contributing to P. aeruginosa’s tolerance to anti-microbial chemotherapy.74,75 Virulence factors 
like lipase, chitinase, elastase and proteases released from P. aeruginosa can cause tissue 
damage, proteolysis imbalance and are thought to be leading cause of immunomodulation.77,285  
Biofilm formation is one of the major systems by which bacteria bypass the chemotherapy.286 
Biofilms are a group of organisms that grow attached to a surface and are embedded in an 
extracellular matrix composed of proteins and exopolysaccharides.74 P. aeruginosa biofilms can 
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cause chronic infections due to increased tolerance to antibiotics and resistance to phagocytosis, 
as well as components of the immune system including innate as well as adaptive resulting in 
immune complex mediated chronic inflammation.286  
Antibiotics such as macrolides are widely used in the treatment of pseudomonal lung 
infections.33,178,287 Macrolides are a group of compounds, which have a large lactone ring in their 
structure.134 The major drug of choice among macrolides is azithromycin, a second generation, 
broad spectrum antibiotic usually used in the treatment of lower respiratory tract infections.288,289 
Azithromycin accumulates effectively in the phagocytes of cells and increases supply to the 
infection sites.131 Azithromycin acts by binding to the 50S subunit of the bacterial ribosome, thus 
inhibiting bacterial protein synthesis. Azithromycin can be used as cell–to-cell blocking agents 
affecting the formation of biofilm in P. aeruginosa.290 In lung diseases such as cystic fibrosis it 
has been proven that azithromycin shows more improved clinical outcomes in patients with 
extended usage.119  On the contrary, study demonstrated that the typical use of azithromycin is 
not effective against P. aeruginosa infections because of the bacterial outer-membrane 
impermeability and efflux pump.33 The main mechanism of macrolide resistance in P. 
aeruginosa biofilms is due to hyperexpression of MexCD-OprJ efflux pump, which plays an 
important role in the antibiotic resistance.291 The MexCD-OprJ efflux pump is mainly expressed 
due to mutations in gene NfxB, which result in the increase of efflux genes and encodes a 
repressor of MexCD-OprJ efflux pump expression.93,292,293 The higher doses of azithromycin 
usage also resulted in increased serum levels and hepatotoxicity due to the failure catalytic 
ability of cytochrome CYP3A4.159 It has been reported that 40 different hydrolytic enzymes 
including proteases, nucleases, glycosidases, lipases, phospholipases, phosphatases, sulfatases  
and many proteins of yet unknown function have been identified to made up of lysosomal 
47 
content,294 among these phospholipase A1 is majorly responsible for the drug induced 
phospholipidosis by azithromycin.295 In addition, the accumulation of azithromycin in lysosomes 
may hinder with phospholipase A1 activity, resulting in storage disorder phospholipidosis 
indicating excess accumulation of phospholipids in the tissues causing inflammatory reactions 
and histopathological alterations in the organs.119,296-298  
To overcome these problems of P. aeruginosa resistance to azithromycin, toxic effects and 
its atypical pharmacokinetics,159 new drug delivery systems like liposomes have been developed. 
Liposomes are considered to be safe, reliable and biodegradable drug delivery systems as they 
are mainly made up of phospholipids and its derivatives, which could increase the efficacy and 
reduce the toxicity associated with the drugs.166,299,300 They are small and round lipid vesicles 
with sizes varying from nanometer to micrometer range.301 It consists of one or more lipid 
bilayers surrounded by an aqueous core.302 It also has a hydrophilic head and hydrophobic tail 
along with the lipid bilayers.303 Usually hydrophilic drugs are incorporated into the aqueous core 
and lipophilic drugs into the bilayers of the phospholipid.304,305 The liposomes show increased 
drug concentrations at the site of infection along with reduced toxic effects.166,201 Previous work 
done by our group showed that erythromycin was able to be encapsulated with higher efficacy 
and more stability.193 Furthermore, Alhajlan et al showed that clarithromycin loaded liposome 
exhibited an increase of antibacterial effects against P. aeruginosa and a decreased toxic effect 
on the human lung cells.236 Oh et al revealed that liposome encapsulated azithromycin or 
ciprofloxacin focus on the reticuloendothelial system, which in turn provide efficient direct 
delivery of antibiotics into the infected cells resulting in a more effective treatment for M. avium 
infections.235  
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In the current work we developed, characterised and evaluated a novel liposomal 
azithromycin formulation for its antimicrobial effects against P. aeruginosa. Liposomal 
azithromycin activity against biofilm forming P. aeruginosa was assessed and the effect of 
subinhibitory concentration of free and liposomal azithromycin was studied on P. aeruginosa 
quorum sensing, virulence factors and  bacterial motility. In addition, the liposome and bacterial 
interactions was investigated. Furthermore, toxicities of the liposomal formulation on 
erythrocytes and cultured A549 lung cells were evaluated in vitro.  
2.2 Materials and methods 
2.2.1 Chemicals and media 
Azithromycin was obtained from Bonn Schtering Bio Sciences (Pondicherry, India). 
Dipalmitoylphosphatidylcholine (DPPC) was purchased from Avanti Polar Lipids, Inc. 
(Alabaster, AL). Cholesterol, Triton X-100, PKH2-GL kit, trypan blue, elastin-congo red, chitin 
azure, β-D-galactopyranoside, RPMI (Roswell park memorial institute medium), DPBS 
(Dulbecco’s phosphate buffered saline) and agarose, were purchased from Sigma-Aldrich 
(Oakville, ON, Canada). Tryptic soy agar, tryptic soy broth, Luria-Bertani (LB) broth, and Luria-
Bertani agar were obtained from Becton Dickinson Microbiology Systems (Oakville, ON, 
Canada). Cell viability assay kit was purchased from Fisher Scientific (Ottawa, ON, Canada). 
Cationic-adjusted Mueller-Hinton (CAMH) broth for culturing microorganisms was purchased 
from Beckton Dickinson (Franklin Lakes, NJ).  
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2.2.2 Cell culture 
A549 human lung carcinoma epithelial cells were obtained from the American Type 
Culture collection (ATCC CCL-185, Manassas, USA) and cultured in Dulbecco’s modified 
eagle’s medium (DMEM) supplemented with 10% heat-inactivated fetal bovine serum (FBS); 
this toxicity study was done without the addition of antibiotics. The cells were grown to 85% 
confluence in 5% CO2 at 37°C and maintained using traditional cell culture techniques.306 
2.2.3 Bacterial strains 
Bacillus subtilis (ATCC 6633) laboratory strain was used as an indicator for testing of 
azithromycin activity. Pseudomonas aeruginosa strain (PAO1) was generously donated by Dr. 
R.E.W. Hancock (University of British Columbia) and Clinical isolates of P. aeruginosa (PA-1, 
PA-5, PA-3, PA-7, PA-M13640, PA-M13641-1, PA-M13641-2, PA-48912-1,PA-48912-2) were  
purchased from PML Microbiologicals (Mississauga, ON, Canada) and some were obtained 
from the Memorial Hospital’s Clinical Microbiology Laboratory (Sudbury, ON, Canada).  All 
the bacterial strains were stored at -80°C in cationic-adjusted Mueller-Hinton (CAMH) broth 
supplemented with 10% glycerol. All strains were grown for 18 h in CAMH broth prior to the 
minimum inhibitory concentrations (MIC) and minimum bactericidal concentrations (MBC), QS, 
and virulence factors experiments. For the Acyl homoserine lactones (AHL) detection 
Agrobacterium tumefaciens strain A136 (pCF218)(pCF372) (Ti-) was used as the biosensor and 
cultured in Luria-Bertani (LB) broth at 30°C. 
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2.2.4 Preparation of liposomes 
The dehydration-rehydration vesicle (DRV) method was used for the preparation of 
liposomes. 1, 2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and cholesterol in a molar 
ratio of 6:1 (lipid to cholesterol) was used. DPPC (0.11382 g) and cholesterol (0.01 g) were 
added to a round bottom flask and then dissolved in sufficient amount of chloroform: methanol 
(2:1) mixture. The mixture in the round bottomed flask was dried to a lipid film with a rotary 
evaporator (Rotavapor; BÜCHI Labortechnik AG) in a water bath at 41°C under controlled 
vacuum (V-800, Brinkman). 0.03 g of azithromycin dissolved in phosphate buffered saline (PBS, 
pH 7.4) was added to rehydrate the lipid film. The lipid suspensions in PBS were vortexed for 
five minutes and then sonicated for 2 minutes (cycles of 45 sec ON and 10 sec OFF) in an ultra-
sonic dismembrator bath (FS20H; Fisher Scientific, Ottawa, Canada) with amplitude of 45Hz 
(Model 500, Fisher Scientific). The lipid suspension was divided into aliquots of tubes. The 
tubes were frozen for 15 min then freeze dried in freeze dry system (Model 77540, Labanco 
Corporation, Kansas city, MO, USA). The obtained powdered formulations were stored in a 
freezer at 0°C until use. For rehydration, 100 µL of PBS was added and the mixture was 
vortexed and incubated for 5 min at 40°C. This step was repeated thrice and finally 700 µL of 
PBS was added to make it 1000 µL of suspension. The excess of unencapsulated drug was 
removed following three rounds of washing with PBS using centrifuge (16000 x g for 15 min at 
4°C).  
2.2.5 Microbiological assay for the measurement of azithromycin 
To measure the encapsulation efficiency (EE) of azithromycin into liposomal vesicles 
laboratory strain Bacillus subtilis (ATCC 6633) was used as an indicator organism as suggested 
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by the Clinical and Laboratory Standards Institute (CLSI). Agar diffusion assay was used to 
quantify the concentrations of azithromycin incorporated into liposomes.306 Bacillus subtilis 
(ATCC  6633) was cultured overnight in CAMH broth, and  a  bacterial  solution  was  prepared 
equivalent to 0.5 McFarland  standards  (1.5  ×  l08 cfu/mL) . The bacterial cells were then added 
to an autoclaved molten agar solution at 41°C and immediately discharged into a sterile glass 
plate (440 mm × 340 mm) to form a thin layer of agar and bacteria. The liposomal azithromycin 
sample was centrifuged at 12,000 × g for 20 min at 4°C and Triton X-100 in PBS 0.2% (vol/vol) 
was added to the obtained pellet in order to release the drug from the liposome.307 We must point 
out that this concentration of Triton X-100 (0.2%) has no effect on the bacterial growth. A well-
puncher device is used to make wells of 5 mm in diameter and filled with 25 µL of liposome 
samples or standard solutions of azithromycin, and the glass plate was incubated for 18 h at 
37°C.308,309After the incubation period of 18 h, inhibition zones obtained in the plate were 
measured in triplicates. In order to quantify the encapsulation efficiency of the liposomal 
azithromycin formulations, average values of the triplicates were used. The sensitivity of the 
microbiological assay was found to be 0.00390 mg/L and quantifiable limit for azithromycin was 
0.003 mg/L. For azithromycin, the standard curve linearity extended over the range of 0.003 to 2 
mg/L and gave a correlation coefficient greater than 0.99. The concentrations of the obtained 
measurements are the means of at least three independent experiments measured in triplicate for 
each experiment. 
2.2.6 Determination of encapsulation efficiency  
The encapsulation efficiency of liposomal azithromycin was determined as the 
percentage of azithromycin entrapped in the liposomes (determined by the microbiological assay 
52 
as mentioned in the previous paragraph) respective to the initial amount of the azithromycin in 
solution.248 The encapsulation efficiency is measured by the formula: 
Encapsulation efficiency (%) =CDRVs/C sol 
CDRVs = Concentration of the antibiotic entrapped in dehydration-rehydration vesicles 
C sol = Initial concentration of the antibiotic added in to the mixture 
The concentration of the entrapped azithromycin in the liposome was determined by the 
microbiological assay as mentioned above. 
2.2.7 Determination of particle size and polydispersity index (PI) 
The mean diameter of liposomes and the polydispersity index (PI) were measured by 
using a Submicron Particle Sizer Model 270 (Nicomp, Santa Barbara, CA).173,308The liposomal 
azithromycin samples obtained after rehydration by adding 1000 µL of PBS were subjected to 
particle size analysis. Liposomal azithromycin were diluted in clear glass tubes with double 
distilled water to get sufficient reading between ranges of 250 to 350 kHz for the photo pulse to 
obtain the particle size data. The process was repeated 2-3 times with the liposomal azithromycin 
sample to take average value of the particle size data. 
2.2.8 Differential scanning calorimetry (DSC) Characterisation 
DSC analysis was performed using the TA Instruments Q100 Differential Scanning 
Calorimeter (Inglehart road, Grimsby, Ontario, Canada). A scan rate of 10°C·min−1 was 
employed with a temperature range of 25°C -200°C. Approximately 5-7 mg sample was used for 
analysis; using an empty pan as reference. Pure DPPC, Physical mixture-1 (DPPC, Cholesterol), 
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Physical mixture-2 (DPPC, Cholesterol and Azithromycin) and azithromycin loaded liposome 
samples were prepared for thermal analysis.310 The measurements of each sample were repeated 
three times. The main phase transition temperatures were determined using TA universal 
analysis 2000 program.  
2.2.9 Stability studies of liposomal azithromycin 
The stability study of liposomal azithromycin was evaluated in PBS at 4°C and 37°C.  
The stability of liposomal azithromycin was measured as the percentage of retention of the initial 
encapsulated azithromycin after the incubation period of time at 4°C and 37°C.248 Briefly, 
liposomal azithromycin was suspended in PBS and incubated in water bath shaker with mild 
agitation at 100 rpm (Julabo SW22 Incubator Shaker; Labortechnik, Seelbach, Germany). After 
incubation times of 0, 2, 4, 6, 8, 24, and 48 h, samples were centrifuged at 18,000 × g for 15 min 
at 4°C to remove the the released drug.248,252The supernatants of the liposomal azithromycin 
samples were collected, and 25 µL was transferred in to puncher-made holes on a plate 
containing agar prepared with B. subtilis ATCC 6633. The plates were then incubated at 37°C 
for 18 h, and the inhibition zones were measured.  
2.2.10 Determination of the minimum inhibitory concentrations (MIC) and minimum 
bactericidal concentrations (MBC)  
The MIC was done on clinical strains of mucoid and non-mucoid P. aeruginosa (PA-1, 
PA-5, PA-3, PA-7, PA-M13640, PA-M13641-1, PA-M13641-2, PA-48912-1, PA-48912-2) by 
the microbroth dilution technique. The bacterial strains were subjected to 0.5 McFarland 
standards and transferred to 96 well plates as reported previously.306 The bacterial strains were 
exposed to different dilutions of azithromycin in the plate. The plates were incubated for 24 h at 
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37°C.44  After incubation MIC results were noted by visually observing the point at which a 
particular concentration of drug inhibits the growth of organisms. The selected concentrations 
were subjected to MBC method by inoculum the sample to the agar plates and incubated for 24 h 
at 37°C to evaluate the growth of bacteria on the plates.247 The results were taken from three 
separate experiments. 
2.2.11 Effect of subinhibitory concentrations of free and liposomal azithromycin on the 
growth of P. aeruginosa   
Culture of P. aeruginosa was used for preparing a bacterial solution equivalent to 0.5 
McFarland (1.5 × l08 bacteria/mL) or OD600=0.13 medium. Then the medium was left in an 
incubator shaker for 1h at 37°C, 250 rpm to double bacterial number to OD600= 0.26 as reported 
previously.311 An equal volume of the antibiotic at 1 MIC, 1/2 MIC, 1/4 MIC, and 1/8 MIC and 
then 25 mL of medium were added to the 5th flask (control). 25 mL of the doubled bacteria was 
added to all flasks to get a total volume of 50 mL solution in each flask. Flasks were then 
incubated at 37°C at 250 rpm. Bacteria cell density was measured spectrophotometrically at 600 
nm every 1 h for 8 h intervals and then growth was measured at 24 h again. The results were 
taken from three separate experiments. 
2.2.12 Determining antibacterial activity of liposomal azithromycin against PAO1 by 
MBEC Assay 
Pseudomonas aeruginosa PAO1 strain was adjusted to 0.5 McFarland standards (1.5×l08 
cfu/mL) were transferred to MBECTM (CBD- Innovotech, AB, Canada) plate and incubated at 37°C for 72-96 h. Every 24 h, broth in the plate was replaced to remove the unattached bacteria 
from lid pegs and the plates with pegs, which were washed with PBS using another 96 welled 
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plate. After 96 h biofilms were harvested from the pegs by using sterile plier and suspended in 
tubes of 900 µL PBS. Sonication was applied to detach bacteria from the pegs for total time 
period of 60 sec with every 10 sec interval for vortexing the tubes. The bacteria were then treated 
with different concentrations of free azithromycin and liposomal azithromycin for 24 h at 37°C.  
The samples of bacteria untreated with drugs were considered as control. The tubes 
containing peg lids with PBS was subjected to 10 fold serial dilution to reduce the concentration 
and 100 µL of each sample were plated on CAMH agar plates for 24 h at 37°C for determination 
of cfu. 
2.2.13 β-Galactosidase activity assay  
The AHL production levels from P. aeruginosa exposed to free and liposomal 
azithromycin at subinhibitory concentrations were tested by measuring the ability of P. 
aeruginosa AHL signaling molecules released into the supernatants to activate the production of 
β-galactosidase in the reporter strain A. tumefaciens (A136).312 Briefly, bioassay tubes containing 
4 mL of reporter strain and 1 mL of supernatant were incubated at 30°C in a water bath for a 
period of 5 h with rotation at 100 rpm. Following with a measurement of the bacterial cell 
density (as the OD 600) prior to the centrifugation. The supernatants were eliminated, and the 
pellets were suspended in an equal volume of Z buffer. The cells were then subjected to 
permeabilization by a solution of 200 µL of chloroform and 100 µL of 0.1% sodium dodecyl 
sulfate prior to the addition of 0.4 mL of o-nitro phenol-β-D-galactopyranoside (4 mg/mL in 
PBS). Once the yellow color was developed, 1 mL of 1 M Na2CO3 was supplemented to stop the 
reaction. The optical densities of the reaction samples were measured at 420 and 550 nm. Miller 
units of β-galactosidase activity was calculated by the formula [(1,000 × A420) – (1.75 ×A550)]/ 
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(time × volume × A600).251,313 Results were represented in residual activity in percentage and 
control used corresponds to 100%.  
2.2.14 Virulence factors assays 
2.2.14.1 Lipase assay 
0.6 mL of filtered supernatant of bacteria, 0.6 mL of Tween® 20 in Tris buffered saline 
(10%), 0.1 mL of CaCl2 (1 M), 1.2 mL H2O were mixed in a 15 mL tube and incubated at 37°C 
for 24 h with agitation at 200 rpm (Innova 4000 Incubator Shaker; New Brunswick scientific, 
NJ). In the presence of lipase, tween is broken down and bound to calcium which precipitates 
and can be measured by turbidity (OD400).314Lipase experiments were done three times in 
triplicates.  
2.2.14.2 Chitinase assay 
The filtered supernatants (1 mL) of bacteria were mixed with 5 mg of insoluble chitin 
azure, and 1 mL of PBS in a 15 mL tube. The mixture was incubated at 37°C for 24 h with 
agitation at 200 rpm (Innova 4000 Incubator Shaker; New Brunswick scientific, NJ). After 
centrifugation (16,000 x g) to remove insoluble chitin azure, the absorbance was measured at 
OD290.314The experiments were repeated three times in triplicates.  
2.2.14.3 Elastase assay 
The filtered supernatants (1 mL) were mixed with 20 mg of insoluble elastin-Congo red, 
and 1 mL of PBS in a 15 mL tube. Elastin-Congo red is insoluble and will sediment at the 
bottom. The mixture was incubated at 37°C for 24 h with agitation on a shaker at 200 rpm 
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(Innova 4000 Incubator Shaker; New Brunswick scientific, NJ).315 If elastase is present, it would 
breakdown and dissolve elastin producing a red colour. By centrifugation (16,000 x g), the 
insoluble elastin-Congo red was removed, and the absorbance was read at OD495. All the elastase 
experiments were done three times in triplicates. 
2.2.14.4 Protease assay 
The filtered supernatants (200 µL) obtained from untreated or treated bacteria were added 
to the wells of Petri dishes (2% agar) containing 3% skim milk was incubated for 48 h at 37°C.316 Mixed the solution to dissolve and poured 25 mL into each Petri dish, and solidified. 
Made holes in the agar with the head of a 1 mL pipette tip and added about 200 µL of the 
supernatants carefully into the hole. Incubate the dishes for 24 h at 37°C. The zones of clearance 
(diameter) around the holes were measured directly from the plates with the use of calipers, with 
three repeats and four replicates, and the experiments were done three times in triplicate.315  
2.2.14.5 Motility studies  
The motility studies were performed as mentioned by other investigators.311 PAO1 grown 
overnight was diluted to 0.5 McFarland standard (1.5 × 108 cfu/mL), and 1µL of PAO1 was 
inoculated onto a 3-mm depth of agar plates containing a subinhibitory concentration of free or 
liposomal azithromycin (1/16 to 1/32 the MIC). Inoculation into the bottom of CAMH broth with 
agarose (1% [wt/vol]) was used for the twitching experiment, and point inoculation onto the 
medium with agarose (0.3% [wt/vol]) was used for swimming and swarming experiments (0.5% 
[wt/vol]). After 12 h of incubation at 37°C, swimming and swarming diameters were measured. 
The zones of twitching at the agarose-petri dish interface with the medium on the dish surface 
was slightly removed after 24 h of incubation at 37°C and then visualized by staining for 1 
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minute with the use of 1% [wt/vol] crystal violet and their diameters were then measured. All the 
swimming, swarming and twitching experiments were performed in three separate experiments 
in triplicate. 
2.2.15 Determination of bacterial membrane fusion with liposomes by flow cytometry 
analysis 
Flow cytometry has been used to evaluate the fusion of liposomes with bacteria. The 
liposomes were labeled with PKH2-GL with the use of a PKH2-GL labeling kit (Sigma, St. 
Louis, MI).317 To study interactions between biological membranes a PHK2-GL probe was used 
in this experiment. In brief, freeze-dried liposomes were rehydrated with PBS  and the obtained 
liposomal pellet was used for the labelling procedure. Labelling was done by following the 
manufacturer’s instructions, in which 1 mL aliquot was taken and centrifuged for 30 min at 6000 
x g under 4°C. The pellet was then resuspended in 1 mL of diluent A (Sigma, St. Louis,MI) and  
8 µL of PHK2-GL was added to the pellet. The PHK2-GL liposomal solution was incubated for 
5 min at room temperature with circular agitation. Following the incubation, 2 mL of bovine 
serum albumin at 1% (w/v) in PBS was added and the solution was further incubated for 1 min 
with agitation to stop the labelling reaction. Liposomes were then washed twice with PBS by 
centrifuging at 5000 x g for 15 min under 4°C to remove any free PKH. Labeling efficiency was 
determined by flow cytometric analysis. 
The Incorporation of liposomes to bacterial cells was demonstrated in a fluorescence-
activated cell sorting (FACS) analysis using the fluorescent marker PKH2-GL. PAO1 were 
incubated for 18 h in MH broth and a solution of 0.3 of OD (660 nm) was then prepared. The 
solution was centrifuged and the bacterial cell pellet was resuspended in RPMI supplemented 
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with 2.5% fetal calf serum for washing. The final cell pellet obtained was resuspended in RPMI 
supplemented with 2.5% fetal calf serum to obtain the same initial concentration. Aliquots of 18 
mL were then taken and transferred to 50 mL flasks. Bacteria were incubated with 200 µL of 
liposomes labeled with PHK2-GL, 200 µL of PBS (negative control) and 80 µL of free PKH-
2GL (positive control). PBS was then added to the flasks to complete the volume to 20 mL and 
the flasks were incubated at 37°C with agitation (250 rpm). Azithromycin was not encapsulated 
in liposomes in order to avoid bacterial cell killing. 2 mL samples were taken after  1,  5 and 10 h 
of incubation. Liposomes were washed with 2 mL of sucrose cushion of 21% (w/v) in PBS to 
eliminate free liposomes and the excess PKH2-GL. The obtained bacterial pellet was washed 
twice in the presence of PBS and the final cell pellet was fixed with 300 µL of 2% formaldehyde 
diluted in PBS for flow cytometry analysis. Samples were analyzed in duplicate and data 
confirmed the slight fusion of liposomes with bacterial cell membranes. The fusion data provided 
by PKH2-GL fluorescence shows the liposome bacterial membrane interactions. 
2.2.16 Cytotoxicity test 
The cell toxicity studies were done by MTT (Methyl thiazol tetrazolium) assay as 
mentioned previously.306In this study, human lung carcinoma epithelial cell line (A549; ATCC, 
Manassas, USA) was used for the cell toxicity assay. The lung cells were maintained in DMEM 
supplemented with 10% fetal bovine serum (FBS). For the MTT assay, the cells were implanted 
in to 96-well plates at a density of 5 x 103 cells/well for sub-confluency. The media was 
eliminated from the wells and replaced with media containing the azithromycin or liposomal 
azithromycin. The untreated cells containing media alone were considered as controls. Further, 
plates were subjected to incubation for 24 h in 5% CO2 at 37°C.  After 24 h of exposure, the well 
was washed once with entire medium and once with DPBS, and replaced with fresh media. MTT 
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dye was supplemented to each well and the plates were incubated in the dark for 4 h at 37°C and 
MTT lysis buffer was then added to each well of the plate. The well plates were further 
incubated in the dark overnight at 37°C, before taking the measurement at 590 nm 
spectrophotometrically. Cytotoxicity studies were illustration of three separate experiments, 
performed in triplicates. 
2.2.17 Hemolytic test 
To further invesitigate the toxicity of liposomal azithromycin hemolytic test was done by 
erythrocyte hemolysis assay as described in previous studies.318,319 The human erythrocytes were 
pooled and subjected to centrifugation (700 x g for 10 minutes at 4°C); they were washed twice 
by centrifugation (700 x g for 10 minutes at 4°C) with ten times the volume of an ice cold buffer. 
Later, the washed erythrocytes were re-suspended in twenty times their quantity of fresh, ice cold 
buffer. In order to perform the hemolysis assay, a 3% erythrocyte solution was prepared by 
suspending the required quantity of erythrocytes into a hemolysis buffer solution. In a shaking 
water bath, erythrocytes were incubated under gentle agitation at 37°C with empty or liposomes 
containing azithromycin up to 24 h. After incubation, erythrocyte samples were removed and 
subjected to centrifugation (1000 x g for 10 min at 4°C).  
The obtained supernatant was discarded and was centrifuged (15000 x g for 15 min at 4°C). In the next step, supernatant was removed and extent of hemoglobin release was measured 
spectrophotometrically at 540 nm. The 3% erythrocytes which stand for 0% hemolysis and red 
blood cells with 1% Triton X-100 indicating 100% red blood cell lysis were considered as 
controls in this study. The hemolysis buffer alone was considered as blank for the measurement. 
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For determining the percentage of hemolysis, blank of hemolysis buffer was subtracted from all 
values obtained and it is estimated by the equation:  
% Hemolysis = (Abs.Sample- Abs.Control 0%)/ (Abs.100% Lysis) x100 
2.2.18 Data analysis 
The data presented as mean ± standard errors of the mean (S.E.M.) of three independent 
experiments. The comparisons of groups were done by one-way analysis of variance (ANOVA) 
with Tukey-Kramer Multiple Comparisons Test by using InStat 3 from Graph Pad prism 
(GraphPad Software Inc., Version 5.0) followed by a post-hocs using t-tests. Probability values 
of *P<0.05, **P<0.01 and ***P<0.001 are considered as statistically significant. 
2.3 Results 
2.3.1 Liposomal azithromycin characterisations and stability  
The mean particle size of liposomes was 406.07 + 45 (nm) and polydispersity index (PI) 
was 0.3 ± 0.03. The encapsulation efficiency of liposomal azithromycin was 23.8 ± 0.2 % and 
concentration of drug entrapped in the liposomes was 0.51 ± 0.004 mg/mL.  
The DSC curves of pure DPPC, physical mixture 1 (DPPC and Cholesterol) and physical 
mixture 2 (DPPC, Cholesterol and azithromycin) are showed in (Figure S1). The melting point 
(Tm) for pure DPPC was found to be 41.98°C. The Tm for physical mixture-1 (DPPC and 
Cholesterol) and physical mixture-2 (DPPC, Cholesterol and Azithromycin) were found to be 
41.96°C and 41.98°C respectively. The melting transition of liposomal azithromycin was found 
to be 40.91°C, which was slightly reduced compare to the physical mixtures 1 and 2. 
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The stability studies of liposomal azithromycin were performed in PBS at 4°C and 37°C 
(Figure S2). The study was performed for a period of 48 h. The liposomal azithromycin stored at 4°C was more stable compared to that stored at 37°C. Retention of liposomal azithromycin at 4°C 
was 95%, whereas at 37°C, the retention was 76.3% at the end of 48 h incubation study period. 
At 2 h of incubation from the initial period liposomal azithromycin retention was decreased to 
94.6% and 80.3% for 4°C and 37°C respectively. 
2.3.2 Determination of the minimum inhibitory concentrations and minimum bactericidal 
concentrations  
The MIC and MBC values of free and liposomal azithromycin against P. aeruginosa are 
presented (Table 4). The experiments were performed on both mucoid and non-mucoid of P. 
aeruginosa strains. The MIC values of liposomal azithromycin against both mucoid and non-
mucoid P. aeruginosa strains were significantly lower than those of free azithromycin. For 
example, the MIC value of P. aeruginosa strain (PAO1) was 16 mg/L for liposomal 
azithromycin and 128 mg/L for free azithromycin. The MBC value of PAO1 was 32 mg/L (42.7 
μM) for liposomal azithromycin whereas, the MBC value for free azithromycin was 256 mg/L 
(341.8 μM). 
2.3.3 Effect of subinhibitory concentrations of free and liposomal azithromycin on the 
growth of P. aeruginosa  
Among all the subinhibitory concentrations (1/2 the MIC to 1/16 the MIC), 1/16 the MIC 
did not inhibit the growth of bacteria as shown in (Figure 1). Liposomal azithromycin at 1/2, 1/4 
and 1/8 the MIC exhibited a significant reduction in bacterial growth (P< 0.001) compared to 
control after 2 h of incubation and throughout the study, thereby liposomal azithromycin and free 
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azithromycin at 1/2, 1/4 and 1/8 the MIC considered as inhibitory concentration. For this reason 
1/16 the MIC and 1/32 the MIC have been selected to show the effect of subinhibitory 
concentrations of free and liposomal azithromycin on the bacterial virulence factors, motility and 
quorum sensing molecules reduction experiments. 
2.3.4 Minimum biofilm eradication concentration assay  
P. aeruginosa biofilm exposed to free and liposomal azithromycin at concentrations 
between 8 mg/L to 1024 mg/L (Figure 2). Liposomal and free formulations were able to 
eradicate bacteria completely at concentrations of 1024 mg/L and 512 mg/L. However, liposomal 
azithromycin formulation at concentrations 256 to 8 mg/L significantly reduced bacterial counts 
compare to control and of free azithromycin P<0.001. For example, Liposomal formulation at 8 
mg/L was more significant in reducing bacterial count compared to 32 mg/L of free azithromycin 
(log10 5.6 versus log10 6.3) (P<0.001). Furthermore, Liposomal formulation significantly reduced 
bacterial count at concentration two times lower than the free formulation (128 versus 256 mg/L) 
(log10 3.7 versus log10  4.4) (P<0.001). 
2.3.5 Quorum sensing molecules reduction 
PAO1 strain was exposed to free azithromycin and liposomal azithromycin at 1/16 the 
MIC and 1/32 the MIC (Figure 3). The decreased levels of Acyl homoserine lactones (AHL) 
from β-galactosidase activity levels indicated a reduced level of AHL signaling molecules. 
Liposomal azithromycin reduced QS molecules compared to control and free formulation. For 
example, liposomal azithromycin at concentration 1/16 MIC exhibited a significant reduction 
effect on QS compared to 1/16 MIC of free azithromycin and control (P<0.001). Furthermore, 
liposomal azithromycin at concentration 1/32 MIC resulted in a significant reduction compared 
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to 1/32 MIC of free azithromycin and control (P<0.01). However, liposomal formulation at 1/16 
the MIC resulted in significant reduction compared to 1/32 the MIC of free formulation 
(P<0.001). 
2.3.6 Effect of liposomal azithromycin on bacterial virulence factors  
The virulence factors like lipase, chitinase, elastase and protease levels of P. aeruginosa 
PAO1 strain when exposed to free and liposomal azithromycin at 1/16 the MIC and 1/32 the 
MIC were examined (Figure 4). Liposomal azithromycin at 1/32 the MIC had a slight effect on 
the lipase production compared to control, whereas free azithromycin had no noticeable effect on 
lipase production (Figure 4a). Furthermore, the liposomal formulation at 1/16 the MIC reduced 
the lipase activity significantly compared to control (P<0.01). For chitinase activity, liposomal 
azithromycin at 1/32 the MIC reduced the chitinase production compared the control (Figure 4b). 
Furthermore, liposomal formulation reduced the chitinase production significantly at 
concentration 1/16 the MIC compared to control (P<0.05). For elastase, free azithromycin did 
not reduce the elastase activity signifacntly compared to control, whereas liposomal 
azithromycin at 1/16 and 1/32 the MIC reduced elastase production significantly compared to 
control (P<0.01) and (P<0.05), respectivly (Figure 4c). Furthermore, liposomal formulation was 
more significant in reducing elastase activity compared to free formulation at 1/16 and 1/32 the 
MIC (P<0.05).  The protease activity was measured by the halo zones formed in the petri dishes 
containing skim milk (Figure 4d). Liposomal azithromycin at concentration of 1/16 the MIC 
significantly reduced the protease production compared to the free azithromycin and control 
(P<0.001). 
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2.3.7 Effect of liposomal azithromycin on bacterial motility 
The P. aeruginosa motility patterns including twitching, swarming and swimming were 
examined in  the presence of the free and liposomal azithromycin at 1/16 the MIC and 1/32 the 
MIC (Figure 5). For motility including twitching, swarming and swimming, the liposomal 
azithromycin at 1/16 the MIC significantly reduced all three motility patterns compared to 1/16 
MIC of free azithromycin (P<0.001). Similarly, liposomal azithromycin at concentration 1/32 
MIC resulted in a significant reduction of different motility patterns compared to 1/32 MIC of 
free azithromycin and control (P<0.001). Significant  results for liposomal azithromycin  were 
obtained in all the patterns in comparision with the controls and free azithromycin (P<0.001). 
2.3.8 Liposome-bacterial interactions by flow cytometry 
Labelled liposomes without antibiotics were utilized to avoid bacterial death due to 
antibiotics. The fusion of Liposomal bilayer-PKH2-GL with PAO1 reached 9.9% within 1 hour 
and reached a maximum of 14.6% after 5 h of contact showing strengthening of liposomes fusion 
with bacteria. The fusion signal reached 12.3% at 10 h of contact before the fluorescent signals 
began declining (Figure 6). A negative panel in the figure indicates the peak of bacterial 
florescence without label, and positive panel were in the range of 50-65% for the duration of the 
experiments. The positive panel assured that PKH2-GL was compatible with the bacterial 
membrane.  
2.3.9 Cytotoxicity and hemolytic tests 
No cytotoxic effect on A459 cells was observed after incubation with liposomal antibiotic 
(100%). However, 90% of the cells were viable in presence of free antibiotic. No significant 
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hemolysis was observed with empty or liposomes containing azithromycin, the hemolytic 
activities were less than 1%. 
2.4 Discussion 
The present study focused on the preparation of novel liposomal azithromycin formulation by 
DRV method.236 Earlier study reported that preparation of liposomes by DRV method resulted in 
higher encapsulation efficiency of macrolide antibiotics with more stability.193 The particle size 
and polydispersity index (PI) of the liposome formulations is one of the important parameter in 
the characterisations that represents the homogeneity of the liposomes and also for determining 
stability for long-term.320 In this study, the obtained results for particle size and polydispersity 
index of liposomal azithromycin formulation were homogenous in nature indicating the long-
term stability.166  
The stability studies are another important considerable parameter while developing a 
novel liposomal formulation. Considering this parameter we performed stability measurement 
for liposomal formulation at different environmental conditions (4°C and 37°C) in PBS for a 
period of 48 h. The obtained data reveals that the retention of liposomal azithromycin at 4°C was 
95% and at 37°C it was 76.3% concluding that the liposomal azithromycin was more stable at 4°C in comparison to 37°C, this is mainly due to the increase in the acyl chain length of lipid 
constituents there by increasing the stability of formulations containing DPPC at higher 
transition temperatures.173 The incorporation of cholesterol during the preparation of liposomes 
may enhance the stability by reducing the bilayer permeability of the liposomal membrane, 
which leads to hike of drug retention at higher temperatures.173,321 After 2 h of incubation from 
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the initial period liposomal azithromycin retention was decreased for both 4°C and 37°C may be 
due to the structural rearrangement of lipid membranes and later to become consistent.322  
 DSC is an analytical technique and it is used for characterising the melting and 
crystallization properties of crystalline materials.323 The data obtained from DSC studies shows 
that slight reduction in the melting transition of liposomal azithromycin when compared to 
physical mixtures (DPPC, Cholesterol and Azithromycin) results from the interactions between 
lipid material and azithromycin. The intercalated drug molecules might disrupt hydrogen bonds 
of liposomes which lead to change in the structural arrangement of lipid layers, thereby reducing 
the melting transition of the azithromycin loaded liposomes.310,324,325 These DSC profile also 
provide a molecular understanding of the interaction between a macrolide antibiotic and 
phospholipids, which could improve understanding of azithromycin–cell interaction.81 The 
molecular interaction of azithromycin and DPPC reveals that phase transition of DPPC is 
strongly decreased due to the increase of gap between hydrophobic chains after incorporation of 
azithromycin into the lipid bilayers.174,326  
          The results from our data demonstrate that the encapsulation of azithromycin into 
liposomes shows more effective anti-microbial activity than the free one against P. 
aeruginosa. The MIC and MBC values of liposomal azithromycin were significantly 8-fold 
lower than the free azithromycin indicating lower MIC values. Similar observations were 
reported by other investigators, showing that the liposome loaded azithromycin effect was 
bactericidal against P. aeruginosa than free drug due to the increased interaction of liposomal 
membrane with bacterial cell membrane were the drug was delivered directly in the cytoplasm of 
the bacteria. 
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          Quorum sensing is the cell-to-cell communication that plays an important role in the 
formation of biofilm and virulence factors production which are contributed to resistance to 
antibiotics.75,327,328Liposomal azithromycin formulation effectively reduced the production of 
quorum sensing molecules at subinhibitory concentrations. The underlying mechanism involved 
may be due to the suppression of las and rhl in the quorum sensing system by azithromycin.329 
The liposomal azithromycin reduced QS more significantly when compared to free 
azithromycin; the possible reason might be due to the increased reduction of chemical signaling 
molecules levels by enhancing antibiotic intake into the cell to fuse with the ribosomes resulting 
in the down regulation of QS genes. The use of liposomes as a drug delivery system may 
increase the efficacy of drugs and the penetration of drugs into the biofilms by longer contact 
with the bacterial biofilm.244,246  
         The liposomal azithromycin at subinhibitory concentrations reduced the production of 
virulence factors including lipase, chitinase, elastase and protease. Earlier studies showed that 
azithromycin reduced different virulence factors at subinhibitory concentrations,328 by 
interference with protein synthesis resulting in the decreased production of virulence factors.330 
Earlier studies showed that liposomes promotes the consumption of encapsulated antibiotic there 
by increase in the down regulation of quorum sensing and virulence factor gene expression or 
also might be due to the reduction of post-transcription synthesis.244,251 A similar kind of result 
demonstrated that clarithromycin loaded liposome reduced different virulence factors 
production.236  
           Many studies reported that macrolide antibiotics at subinhibitory concentrations inhibited 
the bacterial motility, mainly by interfering with the gene expression and affecting the motility 
components of the bacteria.331,332 We determined the effect of our novel liposomal azithromycin 
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formulation by reducing the motility patterns of the bacteria like twitching, swarming and 
swimming. It may have occurred due to the improved delivery of the drug into the bacterial cell 
membranes by liposome loaded drugs, thereby interfering with the motility components like 
flagella and pili of the bacteria as direct delivery of antibiotic in to the cytoplasm of bacteria 
there by inhibiting the flagella and type IV  pilus activities.193,332  
In order to investigate the bacterial cell membrane fusion with liposomes we performed 
FACS analysis. The bacterial fusion was assessed by integration of phospholipid - PKH2-GL in 
bacterial cells. The main characteristic feature of PKH2-GL is used to investigate cell mobility 
and interactions.333 The probe facilitates tracking liposome interaction with the bacterial cell 
membrane by FACS analysis.334 A study showed that the integration of PKH2-GL-labelled 
liposomes with bacterial membranes indicates a direct incorporation of phospholipids into the 
bacterial cell membranes because the probe inserts its aliphatic carbon tails into membranes as 
well as the dissociation of the probe from the liposomes to the bacterial membrane is due to the 
strong hydrophobic nature of the probe.131 The incorporation of PKH2-GL liposomes into 
bacterial membranes confirms the integration of liposomes with bacterial cell membranes. 
Similar results were reported earlier by other investigators supporting this study, which showed 
the enhanced bactericidal effect of liposomal formulation was due to fusion interaction of 
liposomal membrane with bacterial cell membrane.252,317  
              The data from the MTT assay shows that the liposomal azithromycin has no significant 
cytotoxic effect on A549 cells. Exposure of A549 human lung cells to liposomal azithromycin 
reduced its toxicity. In supporting this hypothesis, earlier research showed that the different 
antibiotics loaded liposomal formulations reduced its toxic effects on A549 human lung cells.306 
For the primary assessment of phospholipids toxicity of liposomes, blood is used for better 
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understanding of the toxicity screening of liposomes.319,335 In order to investigate the toxicity of 
liposomal azithromycin the hemolytic test was performed by erythrocyte hemolysis assay. The 
data shows that no reported hemolytic activity with empty or liposomes containing azithromycin 
suggesting that liposomes are non-toxic on human erythrocytes.  
In conclusion, liposomal azithromycin formulation exhibited a significant reduction on P. 
aeruginosa bactericidal concentration, bacterial counts within biofilms, QS molecules, virulence 
factors and motility. Liposomal azithromycin showed no toxicity in vitro and could improve P. 
aeruginosa infection treatment in CF patients. These data indicate that the liposomal formulation 
could be a useful therapy to enhance the safety and efficacy of azithromycin against P. 
aeruginosa lung infection in cystic fibrosis patients. 
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Table and Figure legends: 
Figure 1: Effect of subinhibitory concentrations of free and liposomal azithromycin on 
the growth of PA01 at 1/2 the MIC (a), 1/4 the MIC (b), 1/8 the MIC (c), 1/16 the MIC (d). All 
the experiments were done in triplicate with means standard error of measurement.  
Figure 2: Effect of free and liposomal azithromycin on P. aeruginosa PAO1 biofilm by 
MBEC assay. Free and liposomal azithromycin formulations were injected to the biofilm of 
concentrations from 8 mg/L to 1024 mg/L. The controls were untreated biofilm and data 
represent three independent experiments in triplicate and are shown as means ± SEM. P values 
were considered significant compared with the control: ***P<0.001. 
Figure 3: QS molecules production is measured by β-galactosidase activity. In the 
presence of free and liposomal azithromycin at 1/16 the MIC and 1/32 the MIC, P. aeruginosa 
PAO1 strain was exposed to free and liposomal azithromycin. Then the supernatants were 
collected and incubated with the reporter strain Agrobacterium tumefaciens (A136). The Miller 
unit is used to measure the β-Galactosidase activities. Each bar represents the mean ± S.E.M. of 
three independent experiments. P values were considered significant when compared with the 
control and between groups: ***, P<0.001 and **, P<0.01. 
Figure 4: Effects of subinhibitory concentrations (1/16 the MIC and 1/32 the MIC) of 
free an liposomal azithromycin on virulence factors production of PA01. (a) Lipase. (b) 
Chitinase. (c) Elastase. (d) Protease. The results represented the mean ±SEM in triplicates of 
three independent experiments. The results were normalized by dividing the average absorbance 
of the virulence factor assays over the OD600 (bacterial density) at 24 h for lipase, chitinase, and 
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elastase experiments. P values were considered significant compared with the control: ***, 
P<0.001; **, P<0.01; *, P<0.05. 
Figure 5: Effect of a subinhibitory concentration of liposomal azithromycin on P. 
aeruginosa motility. The motility was examined at  free and  liposomal  azithromycin  at  1/16  
the  MIC and  1/32  the  MIC. Twitching (1% agarose [wt/vol]) (a), swarming (0.5% agarose 
[wt/vol]) (b), and swimming  (0.3%  agarose  [wt/vol]) (c) P values were considered significant 
compared with the control and between groups: ***, P<0.001 and **, P<0.01. 
Figure 6: Flow cytometry histograms- fusion (%) of labelled liposome-PKH2-GL with 
PAO1 at 1, 5 and 10 h intervals. 
Table 4: Antimicrobial activities of both free and liposomal azithromycin. 
 
(M)- Mucoid (NM)- Non mucoid 
  
Lipo AZM(µg/ml)
 MIC MBC MIC MBC
PAO1 (M) 128 256 16 32
PA-13641-1 (NM) 64 128 8 16
PA-13641-2 (M) 512 1024 32 64
PA-48912-1(NM) 128 256 16 32
PA-48912-2(NM) 256 512 32 32
PA-M 13640(M) 512 1024 32 64
PA-1(NM) 512 1024 128 256
PA-5(NM) 256 512 32 64
PA-3(NM) 512 1024 64 128
PA-7(NM) 256 512 16 32
Free AZM(µg/ml)
P. aeruginosa strains
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Figure 1: Effect of subinhibitory concentrations of free and liposomal azithromycin on the growth of PA01. 
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Figure 2: Effect of free and liposomal azithromycin on P. aeruginosa PAO1 biofilm 
by MBEC assay. 
 
Figure 3: QS molecules production is measured by β-galactosidase activity 
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Figure 4: Effects of subinhibitory concentrations of free and liposomal azithromycin on virulence factors production of 
PA01. 
  
89 
 
 
 
Figure 5: Effect of a subinhibitory concentration of liposomal azithromycin on P. 
aeruginosa motility.  
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Figure 6: Flow cytometry histograms- fusion (%) of labelled liposome-PKH2-GL 
with PAO1 
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Supplementary figure legends: 
Figure S1: DSC profile. PM-1: Physical Mixture-1 (DPPC, Cholesterol), PM-2: Physical 
Mixture-2 (DPPC, Cholesterol and Azithromycin) Dashed dot line for liposomal azithromycin, 
Dotted line for PM-2, Dashed line for PM-1, Black line for DPPC.  
Figure S2: Stability profile of liposomal azithromycin.  
Figure S1: 
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Figure S2: 
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3 Conclusion and future directions 
P. aeruginosa is the most significant pathogen involved in the pulmonary infection of 
CF. The effective use of antibiotics such as aminoglycosides, beta-lactams, fluoroquinolones and 
macrolides are found to be useful in the infection control of P. aeruginosa, decreased morbidity 
and increased life expectancy of CF individuals. The encapsulation of antibiotics in the 
liposomes have shown increased antibacterial activity against P. aeruginosa and reduced 
toxicity.  
The main objective of this research is to develop a novel liposomal azithromycin 
formulation and evaluate its antimicrobial effects against P. aeruginosa. We developed a novel 
liposomal formulation loaded with azithromycin prepared by dehydration-rehydration vesicle 
(DRV) method and related characterizations were performed. Liposomal azithromycin activity 
against biofilm forming P.aeruginosa was assessed using Calgary biofilm device (CBD). The 
effect of sub inhibitory concentrations of liposomal azithromycin on bacterial virulence factors 
and motility studies was performed on P.aeruginosa strains. In addition, the bacteria and 
liposome interactions were studied and toxicities were evaluated in vitro. 
Our data indicated that liposomal azithromycin has significant encapsulation efficiency 
and long-term stability. The MIC and MBC values were lower compare to the free azithromycin, 
indicating an effective antimicrobial activity for liposomal azithromycin. Considerably, the 
liposomal azithromycin reduced bacteria formation in the biofilm. At sub-inhibitory 
concentrations, the QS as well as virulence factors such as lipase, chitinase, elastase and protease 
production was mitigated. In addition, the different patterns of bacterial motilities (swimming, 
swarming and twitching) were restricted. Flow cytometry analysis showed remarkable 
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interactions between liposomes and bacterial membrane. Neither lung cell toxicity nor significant 
erythrocyte lysis was observed by liposomal azithromycin.  
Based on our in vitro data, our liposomal azithromycin formulation could be an effective 
and therapy against P. aeruginosa lung infection in CF patients.  In conclusion, liposomal drug 
delivery systems are result-driven and provide considerable option for treatment of chronic lung 
infections. 
In the future, this research could be carried forward to evaluate efficacy in the P. 
aeruginosa infected animal models. It would also be remarkable to explore the mechanism of 
action of inhibiting virulence factors and QS molecules by liposomal azithromycin.  
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